Objective:To explore the risk assessment and prevention management of hospital-associated venous thromboembolism (HA-VTE) in plateau area.Methods:This was a prospective observational study. A total of 200 patients hospitalized for acute medical diseases or surgery in the People′s Hospital of Tibet Autonomous Region from May to June 2022 were consecutively enrolled. Padua score or Caprini risk assessment model was used for dynamic risk assessment and stratification of VTE in all patients. At the same time, bleeding risk was assessed according to age, complications, trauma history, drug therapy, invasive procedures and other factors. The implementation of mechanical and/or drug prophylaxis was dynamically recorded during hospitalization. The change of VTE risk and prevention during hospitalization were the primary outcome, and the occurrence of HA-VTE events and bleeding events during hospitalization or within 90 days after enrollment were the secondary outcome.Results:A total of 196 patients were enrolled in the study, including 130 (66.3%) in internal medicine and 66 (33.7%) in surgery. There were 64 (49.2 %) and 27 (40.9%) patients with high risk of VTE within 1 day after admission among medical and surgical patients, respectively. During hospitalization, 58 (44.6%) and 49 (74.2%) patients with high risk of VTE were re-evaluated among medical and surgical patients, respectively. There were 39 (30.0%) medical patients and 54 (81.8%) surgical patients who had an increased risk of VTE due to changes in their conditions. In terms of VTE prevention, 32 patients (16.3%) received VTE prophylaxis, only 17 medical patients (8.7%) with high risk of VTE received drug prophylaxis, and 2 patients (1.0%) with high risk of VTE developed HA-VTE events after drug prophylaxis. A total of 8 (4.1%) surgical patients received drug prophylaxis, of which 1 (0.5%) received mechanical prophylaxis at the same time, and no surgical patients experienced HA-VTE events after prophylaxis. HA-VTE events occurred in 11 patients (5.6%) during hospitalization or within 90 days after enrollment.Conclusion:Considering the complex and changeable risk factors of VTE, insufficient VTE prevention and high incidence of HA-VTE in hospitalized patients in plateau areas, Padua score and Caprini risk assessment model are recommended for early, dynamic and full VTE risk assessment of patients, so as to standardize the VTE prevention and improve the quality of health management of hospitalized patients in plateau areas.

Objective To analyze and evaluate the CT and MRI features of synovial sarcoma (SS).Methods Clinical and imaging data of 25 cases with SS confirmed by pathology were retrospectively analyzed.1 5 cases with CT scan,including 1 1 contrastGenhanced CT scan,and 1 2 cases with MRI scan,including 8 contrastGenhanced MRI scan.Results Among 25 cases,1 8 were located in the lower extremities,2 in the upper extremities and in the chest wall respectively,1 case in the lung parenchyma,mediastinum and spine respectively.1 8 cases were deep seated,while 1 9 cases were lobulated.On CT image,most of the lesions were isodense or hypodense to muscle,while 3 cases presented peripheral calcification,and 9 cases showed progressive enhancement.On MRI,10 cases were isointense or slight hypointense on T1 WI,while 9 cases presented hyperintense or slight hyperintense on T2 WI.9 cases showed cystic change (7 of them located in the periphery),and 8 cases showed short T1 signal.3 cases demonstrated "fluidGfluid levels",and 9 cases exhibited hypointense septa.7 cases revealed "triple sign"on T2 WI and 7 cases showed obviously heterogenous enhancement.Conclusion Synovial sarcomas are mostly located in the lower extremities,with clear margins,peripheral cystic changes,intramural hemorrhage,"triple sign"on T2 WI and progressive enhancement.

Humans ; Hospital Mortality ; Pulmonary Embolism ; Comorbidity ; Registries ; Neoplasms/complications*

Zhishi Xiebai Guizhitang is a classical prescription for the treatment of chest impediment with the method of warming Yang. It is included in the Catalogue of Ancient Classical Prescriptions issued by the National Administration of Traditional Chinese Medicine （First Batch）， with the effect of activating Yang， dissipating mass， moving Qi and resolving phlegm. Its main symptoms include chest fullness and pain， or even chest pain radiating to the back， wheezing， coughing， shortness of breath， and Qi reversal from the hypochondrium. In modern traditional Chinese medicine， Zhishi Xiebai Guizhitang is clinically used in the treatment of cardiovascular system， digestive system， respiratory system and other diseases， among which coronary heart disease， unstable angina pectoris， myocardial infarction， sinus bradycardia and other cardiovascular diseases have particularly significant effects. This paper reviewed the pharmacological studies of Zhishi Xiebai Guizhitang in the past 10 years. The results showed that each single medicine and the whole prescription alleviated the above cardiovascular diseases to a certain extent， with the pharmacological effects of improving intravascular environment， myocardial ischemia， myocardial ischemia-reperfusion injury， and myocardial hypoxia， anti-inflammation， plaque stabilisation， etc.， and the pharmacological mechanism involved the regulation of relevant active substances in vivo as well as related signaling pathways and ion channels， mainly including thromboxane B₂ （TXB₂）， prostacyclin I₂（PGI₂） and phosphatidylinositol 3-kinases/protein kinase B/endothelial nitric oxide synthase （PI3K/Akt/eNOS） signaling pathways， and ATP-sensitive potassium channels. In addition， the relationship between the pharmacological effects of some single medicines and transient receptor potential ankyrin 1 （TRPA1） has been reported that TRPA1 is a key to understanding the mechanism of Zhishi Xiebai Guizhitang in treating cardiovascular diseases， which is worth of further study.